PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Mizolastine - Allergic rhinitis
PAD Profile : Mizolastine - Allergic rhinitis
Keywords :
Hay fever, hayfever, antihistamines, allergy, seasonal allergic rhinitis, pollen allergy, non-sedating antihistamines
Brand Names Include :
Mizollen
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Cetirizine hydrochloride
- Loratadine
- Desloratadine
- Levocetirizine
- Bilastine
- Acrivastine
- Fexofenadine hydrochloride
- Rupatadine fumarate
- House dust mites allergen extract
- White Birch pollen allergen extract
- Chlorphenamine maleate
- Ketotifen fumarate
- Promethazine hydrochloride
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
05 April 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
Mizolastine is not recommended as a routine treatment in local guidelines - see below.
Mizolastine 10mg MR tablets have been implicated in causing abnormal prolongation of the QT interval
Associated BNF Codes
03. Respiratory System
03.04.01. Antihistamines